211 related articles for article (PubMed ID: 10189894)
1. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
Sadzuka Y; Hirotsu S; Hirota S
Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
[TBL] [Abstract][Full Text] [Related]
2. Effective prodrug liposome and conversion to active metabolite.
Sadzuka Y
Curr Drug Metab; 2000 Jul; 1(1):31-48. PubMed ID: 11467079
[TBL] [Abstract][Full Text] [Related]
3. Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.
Sadzuka Y; Hirotsu S; Hirota S
Cancer Lett; 1998 May; 127(1-2):99-106. PubMed ID: 9619864
[TBL] [Abstract][Full Text] [Related]
4. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
Bissery MC; Vrignaud P; Lavelle F; Chabot GG
Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
6. Liposomalization of SN-38 as active metabolite of CPT-11.
Sadzuka Y; Takabe H; Sonobe T
J Control Release; 2005 Nov; 108(2-3):453-9. PubMed ID: 16182400
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
Kaneda N; Hosokawa Y; Yokokura T; Awazu S
Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan (CPT-11): a brief overview.
Rivory LP
Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
[TBL] [Abstract][Full Text] [Related]
9. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
[TBL] [Abstract][Full Text] [Related]
11. Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation.
Wang W; Ghandi A; Liebes L; Louie SG; Hofman FM; Schönthal AH; Chen TC
J Neurosurg; 2011 Mar; 114(3):689-94. PubMed ID: 20415520
[TBL] [Abstract][Full Text] [Related]
12. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of SN-38 in rats and tissue distribution of 7-ethyl-10-hydroxycamptothecin in mice after intravenous injection of irinotecan hydrochloride nanoparticles].
Yang FY; Zhang WP; Wang XY; Yang WC; Dang HW
Yao Xue Xue Bao; 2014 Jul; 49(7):1029-33. PubMed ID: 25233635
[TBL] [Abstract][Full Text] [Related]
14. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
15. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.
Hattori Y; Shi L; Ding W; Koga K; Kawano K; Hakoshima M; Maitani Y
J Control Release; 2009 May; 136(1):30-7. PubMed ID: 19331859
[TBL] [Abstract][Full Text] [Related]
16. Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.
Park DJ; Won JH; Cho AR; Yun HJ; Heo JH; Hwhang TH; Lee DH; Kim WM
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 962():147-152. PubMed ID: 24927278
[TBL] [Abstract][Full Text] [Related]
17. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
19. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity.
Zhang Z; Yao J
AAPS PharmSciTech; 2012 Sep; 13(3):802-10. PubMed ID: 22639238
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
